Skip to nav Skip to content
Frederick  Locke

Frederick Locke, MD

Program Lead, Blood and Marrow Transplant and Cellular Immunotherapy
Research Department Chair, Blood and Marrow Transplant and Cellular Immunotherapy
Research Program Lead, Immuno-Oncology Program
Program Co-Leader, Immuno-Oncology; Chair, Department of Blood and Marrow Transplant and Cellular Immunotherapy

Program: Blood and Marrow Transplant and Cellular Immunotherapy

Research Program: Immuno-Oncology Program

Google Scholar Profile

Contact

  • Overview

    Dr. Locke is focused on developing strategies to promote T cell responses against tumor associated antigens for patients with cancer.

    Associations

    • Blood and Marrow Transplant and Cellular Immunotherapy
    • Immunology
    • BioEngineering
    • Immuno-Oncology Program
    • Experimental Therapeutics Program
    • Center of Excellence for Evolutionary Therapy

    Education & Training

    Board Certification:

      Fellowship:

      • University of Chicago Medical Center - Hematology/Oncology

      Residency:

      • Wayne State University/Detroit Medical Center - Internal Medicine

      Medical School:

      • Wayne State University - MD
    • Research Interest

      Dr. Locke is a physician and translational investigator specializing in the treatment of lymphoma and multiple myeloma in the Department of Blood and Marrow Transplantation at Moffitt. He is focused on developing strategies to promote T cell responses against tumor associated antigens for patients with these diseases and is the principal investigator for multiple cellular immunotherapy trials. He is a lead investigator for two national multi-center phase I/II studies treating aggressive lymphoma patients with anti-CD19 CAR T cells and the site PI of a randomized multi-center trial testing infusion of tumor (marrow) infiltrating lymphocytes for multiple myeloma. Dr. Locke’s translational research evaluates T cell responses against tumor associated antigens and neoantigens in myeloma patients. His findings justified a trial evaluating the biological activity of a unique Moffitt-created survivin dendritic cell vaccine using a novel schedule in conjunction with autologous transplant. Dr. Locke is the Chair of the Moffitt Cellular Therapy Advisory Committee and the Chair of the Moffitt Immunotherapy Working Group. In addition he is the Service Chief of the Moffitt Immune and Cellular Therapy (ICE-T) service, which was created to provide specialized clinical care for patients undergoing cellular immunotherapy treatments.

    • Participating Trials

      Clinical Trial 19724
      Managed Access Program (MAP) To Provide Access To CTL019, For Acute Lymphoblastic Leukemia (ALL) Or Diffuse Large B-Cell Lymphoma (DLBCL) Patients With Out Of Specification Leukapheresis Product And/Or Manufactured Tisagenlecleucel Out Of Specification For Commercial Release
      Condition: Malignant Hematology
      Status: Open

      Clinical Trial 20571
      Optimizing Cellular and Humoral Immunity to Pneumococcus by Vaccination with Pneumococcal 13-valent conjugate vaccine before and after CD19-targeted CAR T-cell Immunotherapy
      Condition: Immunotherapy
      Intervention: CD19 CAR T Cells (); PCV13 ()
      Status: Open

      Clinical Trial 20578
      A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmocodynamics of ALLO-501A, an Anti-CD19 Allogeneic Car T Cell Therapy in Subjects with Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
      Condition: Malignant Hematology
      Intervention: ALLO-501 (); ALLO-501A (); ALLO-647 (); Not Applicable (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
      Status: Open

      Clinical Trial 20737
      Expanded Access Protocol (EAP) for Subjects Receiving Lisocabtagene Maraleucel That is Nonconforming for Commercial Release
      Condition: Malignant Hematology
      Intervention: cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate); lisocabtagene maraleucel ()
      Status: Open

      If you believe you are eligible for one of these trials or studies, please call
      813-745-6100 or toll-free 1-800-679-0775.

    • Publications

      • Hashmi H, Hansen DK, Peres LC, Puglianini OC, Freeman C, De Avila G, Sidana S, Shune L, Sborov DW, Davis J, Wagner C, Kocoglu MH, Atrash S, Voorhees P, Simmons G, Ferreri C, Kalariya N, Anderson LD, Afrough A, Dima D, Khouri J, McGuirk J, Locke F, Baz R, Patel KK, Alsina M. Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience. Haematologica. 2024 May.109(5):1514-1524. Pubmedid: 37855036. Pmcid: PMC11063864.
      • Gardner RA, White C, Elsallab M, Farnia S, Fraint E, Grilley B, Bateman-House A, Grupp SA, Kenderian S, Locke FL, Nikiforow S, Oluwole OO, Rouce RH, Spiegel J, Shah NN, Sharma A, Komanduri K, Gill S. ACT To Sustain: Adoptive Cell Therapy To Sustain Access to Non-Commercialized Genetically Modified Cell Therapies. Transplant Cell Ther. 2024 May. Pubmedid: 38762057.
      • Zhang Y, Rose A, Khadka S, Cao B, Eatrides J, Saeed H, Shah BD, Chavez J, Bello C, Lazaryan A, Khimani F, Ibarz JP, Liu HD, Locke FL, Jain MD, Zhang L, Kharfan-Dabaja MA, Kim J, Ayala E, Nishihori T, Sokol L. Autologous Hematopoietic Cell Transplantation Consolidation for First Response is Associated With Longer Survival Among Patients With Nodal Peripheral T Cell Lymphoma. Transplant Cell Ther. 2024 May. Pubmedid: 38740140.
      • Lunning MA, Wang HL, Hu ZH, Locke FL, Siddiqi T, Jacobson CA, Ahmed S, Miklos DB, Lin Y, Hill BT, Ghobadi A, Neelapu SS, Westin J, Dieyi C, Field P, Miao H, Shahani SA, Patel A, Spooner C, Fu C, Muramoto D, Xu H, Pasquini MC. Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy. Am J Hematol. 2024 May.99(5):880-889. Pubmedid: 38504387.
      • Faramand RG, Lee SB, Jain MD, Cao B, Wang X, Rejeski K, Subklewe M, Fahrmann JF, Saini NY, Hanash SM, Kang YP, Chang D, Rodriguez PC, Dean EA, Nishihori T, Shah BD, Lazaryan A, Chavez J, Khimani F, Pinilla-Ibarz JA, Dam M, Reid KM, Corallo SA, Menges M, Hidalgo Vargas M, Mandula JK, Holliday BA, Bachmeier CA, Speth K, Song Q, Mattie M, Locke FL, Davila ML. Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma. Blood Cancer Discov. 2024 Mar.5(2):106-113. Pubmedid: 38194367. Pmcid: PMC10905320.
      • Akhtar OS, Modi K, Kim J, Skellson L, Smith E, Al-Jumayli MA, Extermann M, De Avila G, Parker N, Castaneda-Puglianini O, Grajales-Cruz A, Baz R, Blue B, Shain K, Alsina M, Liu H, Nishihori T, Jain MD, Locke FL, Hansen DK, Freeman CL. Simple Score of Albumin and CRP Predicts High-Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy. Transplant Cell Ther. 2024 Mar.30(3):283.e1-283.e10. Pubmedid: 38123069.
      • Sidana S, Peres LC, Hashmi H, Hosoya H, Ferreri C, Khouri J, Dima D, Atrash S, Voorhees P, Simmons G, Sborov DW, Kalariya N, Hovanky V, Bharadwaj S, Miklos D, Wagner C, Kocoglu MH, Kaur G, Davis JA, Midha S, Janakiram M, Freeman C, Alsina M, Locke F, Gonzalez R, Lin Y, McGuirk J, Afrough A, Shune L, Patel KK, Hansen DK. Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment. Haematologica. 2024 Mar.109(3):777-786. Pubmedid: 37731379. Pmcid: PMC10905101.
      • Akhtar OS, Sheeba BA, Azad F, Alessi L, Hansen D, Alsina M, Baz R, Shain K, Grajales Cruz A, Castaneda Puglianini O, Liu H, Blue B, Nishihori T, Al Jumayli M, Extermann M, Locke FL, Mhaskar R, Freeman CL. Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: A systematic review and meta-analysis. Geriatr Oncol. 2024 Mar.15(2):101628. Pubmedid: 37723045.
      • Chavez JC, Grajales A, Sandoval-Sus J, Turba E, Nodzon L, Uriepero-Palma A, Ammad-Ud-Din M, Sahakian E, Komrokji R, Sokol L, Locke FL, Shah B, Lancet J, Sotomayor EM, Kharfan-Dabaja MA, Bello C, Pinilla-Ibarz J. Long-term follow up of the combination of ofatumumab, high-dose methylprednisolone, and lenalidomide for untreated chronic lymphocytic leukemia with biomarker analysis. Clin Lymphoma Myeloma Leuk. 2024 Jun.24(6):382-391.e2. Pubmedid: 38508880.
      • Locke FL, Oluwole OO, Kuruvilla J, Thieblemont C, Morschhauser F, Salles GA, Rowe SP, Vardhanabhuti S, Winters J, Filosto S, To C, Cheng P, Schupp M, Korn R, Kersten MJ. Axicabtagene ciloleucel vs standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume. Blood. 2024 Jun.143(24):2464-2473. Pubmedid: 38557775.
      • Oluwole OO, Neelapu SS, Ray MD, Limbrick-Oldfield EH, Wade SW, Kanters S, Patel AR, Locke FL. Network meta-analysis of CAR T-Cell therapy for the treatment of 3L+ R/R LBCL after using published comparative studies. Expert Rev Anticancer Ther. 2024 Jun.24(6):457-465. Pubmedid: 38646700.
      • Ghobadi A, Munoz J, Westin JR, Locke FL, Miklos DB, Rapoport AP, Perales MA, Reagan PM, McGuirk JP, Jacobson CA, Kersten MJ, Avivi I, Peng A, Schupp M, To C, Oluwole OO. Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7. Blood Adv. 2024 Jun.8(11):2982-2990. Pubmedid: 38315832.
      • Peres LC, Oswald LB, Dillard CM, De Avila G, Nishihori T, Blue BJ, Freeman CL, Locke FL, Alsina M, Castaneda Puglianini OA, Shune L, Sborov DW, Wagner C, Dima D, Hashmi H, Davis JA, Kocoglu MH, Badros AZ, Atrash S, Simmons G, Kalariya N, Ferreri CJ, Anderson LD, Afrough A, Kaur G, Lin Y, Liu L, Nadeem O, Voorhees PM, Khouri J, McGuirk JP, Sidana S, Hansen DK, Patel KK. Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy. Blood Adv. 2024 Jan.8(1):251-259. Pubmedid: 37855718.
      • Oluwole OO, Ray MD, Davies N, Bradford R, Jones C, Patel AR, Locke FL. Cost-effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for the treatment of 3L + relapsed/refractory large B-cell lymphoma in the United States: incorporating longer survival results. J Med Econ. 2024 Jan.27(1):230-239. Pubmedid: 38240256.
      • Oluwole OO, Dholaria B, Knight TE, Jain T, Locke FL, Ramsdell L, Nikiforow S, Hashmi H, Mooney K, Bhaskar ST, Morris K, Gatwood K, Baer B, Anderson LD, Hamadani M. Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther. 2024 Feb.30(2):131-142. Pubmedid: 37951502.
      • Jain MD, Jacobs MT, Gao F, Nastoupil LJ, Spiegel JY, Lin Y, Dahiya S, Lunning MA, Lekakis LJ, Reagan PM, Oluwole OO, McGuirk JP, Deol A, Sehgal A, Goy A, Hill BT, Andreadis C, Munoz J, Chavez JC, Bennani NN, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Locke FL, Ghobadi A. Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium. Blood Adv. 2024 Feb.8(4):1042-1050. Pubmedid: 38051550. Pmcid: PMC10920102.
      • Elmariah H, Otoukesh S, Kumar A, Ali H, Arslan S, Shouse G, Pourhassan H, Nishihori T, Faramand R, Mishra A, Khimani F, Fernandez H, Lazaryan A, Nieder M, Perez L, Liu H, Nakamura R, Pidala J, Marcucci G, Forman SJ, Anasetti C, Locke F, Bejanyan N, Al Malki MM. Sirolimus Is an Acceptable Alternative to Tacrolimus for Graft-versus-Host Disease Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplant Cell Ther. 2024 Feb.30(2):229.e1-229.e11. Pubmedid: 37952648.
      • Levine BL, Pasquini MC, Connolly JE, Porter DL, Gustafson MP, Boelens JJ, Horwitz EM, Grupp SA, Maus MV, Locke FL, Ciceri F, Ruggeri A, Snowden J, Heslop HE, Mackall CL, June CH, Sureda AM, Perales MA. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat Med. 2024 Feb.30(2):338-341. Pubmedid: 38195751.
      • Locke FL, Filosto S, Chou J, Vardhanabhuti S, Perbost R, Dreger P, Hill BT, Lee C, Zinzani PL, Kröger N, López-Guillermo A, Greinix H, Zhang W, Tiwari G, Budka J, Marincola FM, To C, Mattie M, Schupp M, Cheng P, Bot A, Shen R, Bedognetti D, Miao H, Galon J. Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma. Nat Med. 2024 Feb.30(2):507-518. Pubmedid: 38233586. Pmcid: PMC10878966.
      • Locke FL, Siddiqi T, Jacobson CA, Ghobadi A, Ahmed S, Miklos DB, Perales MA, Munoz J, Fingrut WB, Pennisi M, Gauthier J, Shadman M, Gowda L, Mirza AS, Abid MB, Hong S, Majhail NS, Kharfan-Dabaja MA, Khurana A, Badar T, Lin Y, Bennani NN, Herr MM, Hu ZH, Wang H, Baer A, Baro E, Miao H, Spooner C, Xu H, Pasquini MC. Real-World and Clinical Trial Outcomes in Large B-cell Lymphoma with Axicabtagene Ciloleucel Across Race and Ethnicity. Blood. 2024 Apr. Pubmedid: 38635762.
      • Rejeski K, Wang Y, Hansen DK, Iacoboni G, Bachy E, Bansal R, Penack O, Müller F, Bethge WA, Munoz J, Mohty R, Bücklein VL, Barba P, Locke FL, Lin Y, Jain MD, Subklewe M. Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality. Blood Adv. 2024 Apr.8(8):1857-1868. Pubmedid: 38181508. Pmcid: PMC11007437.
      • Afrough A, Hashmi H, Hansen DK, Sidana S, Ahn C, Peres LC, Dima D, Freeman CL, Puglianini OC, Kocoglu MH, Atrash S, Voorhees PM, Shune L, McGuirk JP, Simmons G, Sborov DW, Davis JA, Kaur G, Sannareddy A, Ferreri CJ, Gaballa MR, Goldsmith S, Nadeem O, Midha S, Wagner CB, Locke FL, Patel KK, Khouri J, Anderson LD, Lin Y. Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium. Blood Cancer J. 2024 Apr.14(1):63. Pubmedid: 38609386. Pmcid: PMC11015040.
      • Oswald LB, Gudenkauf LM, Li X, De Avila G, Peres LC, Kirtane K, Gonzalez BD, Hoogland AI, Nguyen O, Rodriguez Y, Baz RC, Shain KH, Alsina M, Locke FL, Freeman C, Castaneda Puglianini O, Nishihori T, Liu H, Blue B, Grajales-Cruz A, Jim HSL, Hansen DK. Patient-Reported Outcomes among Multiple Myeloma Patients Treated with Standard of Care Idecabtagene Vicleucel. Cancers (Basel). 2023 Sep.15(19). Pubmedid: 37835405. Pmcid: PMC10571575.
      • Rejeski K, Perez A, Iacoboni G, Blumenberg V, Bücklein VL, Völkl S, Penack O, Albanyan O, Stock S, Müller F, Karschnia P, Petrera A, Reid K, Faramand R, Davila ML, Modi K, Dean EA, Bachmeier C, von Bergwelt-Baildon M, Locke FL, Bethge W, Bullinger L, Mackensen A, Barba P, Jain MD, Subklewe M. Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion. Sci Adv. 2023 Sep.9(38):eadg3919. Pubmedid: 37738350. Pmcid: PMC10516499.
      • Epperla N, Kumar A, Abutalib SA, Awan FT, Chen YB, Gopal AK, Holter-Chakrabarty J, Kekre N, Lee CJ, Lekakis L, Lin Y, Mei M, Nathan S, Nastoupil L, Oluwole O, Phillips AA, Reid E, Rezvani AR, Trotman J, Zurko J, Kharfan-Dabaja MA, Sauter CS, Perales MA, Locke FL, Carpenter PA, Hamadani M. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma. Transplant Cell Ther. 2023 Sep.29(9):548-555. Pubmedid: 37419325.
      • Elmarsafawi AG, Hesterberg RS, Fernandez MR, Yang C, Darville LN, Liu M, Koomen JM, Phanstiel Iv O, Atkins R, Mullinax JE, Pilon-Thomas SA, Locke FL, Epling-Burnette PK, Cleveland JL. Modulating the polyamine/hypusine axis controls generation of CD8+ tissue-resident memory T cells. JCI Insight. 2023 Sep.8(18). Pubmedid: 37581943. Pmcid: PMC10561731.
      • Freeman CL, Locke FL. CARs put age in the rearview mirror. Blood. 2023 Sep.142(12):1029-1031. Pubmedid: 37733380.
      • Westin JR, To C, Locke FL. Axicabtagene Ciloleucel in Large B-Cell Lymphoma. Reply. N Engl J Med. 2023 Sep.389(12):1152-1153. Pubmedid: 37733323.
      • Akhtar OS, Cao B, Wang X, Torka P, Al-Jumayli M, Locke FL, Freeman CL. CAR T-cell therapy has comparable efficacy with autologous transplantation in older adults with DLBCL in partial response. Blood Adv. 2023 Oct.7(19):5937-5940. Pubmedid: 37236167. Pmcid: PMC10562759.
      • Ibrahim U, Bassil C, Chavez JC, Khimani F, Jain MD, Locke FL, Lazaryan A, Osman K. CAR T Cell Therapy for Post-Transplant Lymphoproliferative Disorder After Solid Organ Transplantation: A Safe and Feasible Therapy for an Orphan Disease. Clin Lymphoma Myeloma Leuk. 2023 Oct.23(10):772-778. Pubmedid: 37263876.
      • Rejeski K, Wang Y, Albanyan O, Munoz J, Sesques P, Iacoboni G, Lopez-Corral L, Ries I, Bücklein VL, Mohty R, Dreyling M, Baluch A, Shah B, Locke FL, Hess G, Barba P, Bachy E, Lin Y, Subklewe M, Jain MD. The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL. Am J Hematol. 2023 Nov.98(11):1699-1710. Pubmedid: 37584447. Pmcid: PMC10659121.
      • Freeman CL, Atkins R, Varadarajan I, Menges M, Edelman J, Baz R, Brayer J, Castaneda Puglianini O, Ochoa-Bayona JL, Nishihori T, Shain KH, Shah B, Chen DT, Kelley L, Coppola D, Alsina M, Antonia S, Anasetti C, Locke FL. Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma. Clin Cancer Res. 2023 Nov.29(22):4575-4585. Pubmedid: 37735756.
      • Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff PJ, Flinn IW, Farooq U, Goy A, McSweeney P, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Bot AA, Shen RR, Dong J, Singh K, Miao H, Kim JJ, Zheng Y, Locke FL. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2023 May.141(19):2307-2315. Pubmedid: 36821768.
      • Wang Y, Jain P, Locke FL, Maurer MJ, Frank MJ, Munoz JL, Dahiya S, Beitinjaneh AM, Jacobs MT, Mcguirk JP, Vose JM, Goy A, Andreadis C, Hill BT, Dorritie KA, Oluwole OO, Deol A, Paludo J, Shah B, Wang T, Banerjee R, Miklos DB, Rapoport AP, Lekakis L, Ghobadi A, Neelapu SS, Lin Y, Wang ML, Jain MD. Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium. J Clin Oncol. 2023 May.41(14):2594-2606. Pubmedid: 36753699.
      • Westin JR, Locke FL, Dickinson M, Ghobadi A, Elsawy M, van Meerten T, Miklos DB, Ulrickson ML, Perales MA, Farooq U, Wannesson L, Leslie L, Kersten MJ, Jacobson CA, Pagel JM, Wulf G, Johnston P, Rapoport AP, Du L, Vardhanabhuti S, Filosto S, Shah J, Snider JT, Cheng P, To C, Oluwole OO, Sureda A. Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma. Clin Cancer Res. 2023 May.29(10):1894-1905. Pubmedid: 36999993. Pmcid: PMC10183830.
      • Jain T, Olson TS, Locke FL. How I treat cytopenias after CAR T-cell therapy. Blood. 2023 May.141(20):2460-2469. Pubmedid: 36800563.
      • Dong N, Lopes-Garcia LR, Viñal D, Bachmeier C, Shah BD, Nishihori T, Khimani F, Davila ML, Lazaryan A, Pinilla-Ibarz J, Locke FL, Jain MD, Chavez JC. Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular Lymphoma. Transplant Cell Ther. 2023 Jun.29(6):349.e1-349.e8. Pubmedid: 36878427.
      • Rejeski K, Hansen DK, Bansal R, Sesques P, Ailawadhi S, Logue JM, Bräunlein E, Cordas Dos Santos DM, Freeman CL, Alsina M, Theurich S, Wang Y, Krackhardt AM, Locke FL, Bachy E, Jain MD, Lin Y, Subklewe M. The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma. J Hematol Oncol. 2023 Jul.16(1):88. Pubmedid: 37525244. Pmcid: PMC10391746.
      • Westin JR, Oluwole OO, Kersten MJ, Miklos DB, Perales MA, Ghobadi A, Rapoport AP, Sureda A, Jacobson CA, Farooq U, van Meerten T, Ulrickson M, Elsawy M, Leslie LA, Chaganti S, Dickinson M, Dorritie K, Reagan PM, McGuirk J, Song KW, Riedell PA, Minnema MC, Yang Y, Vardhanabhuti S, Filosto S, Cheng P, Shahani SA, Schupp M, To C, Locke FL. Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma. N Engl J Med. 2023 Jul.389(2):148-157. Pubmedid: 37272527.
      • Barata A, Hoogland AI, Small BJ, Locke FL, Jim HSL. Response to: Perceived Cognitive Changes Following Chimeric Antigen Receptor T Cell Therapy in Lymphoma: Perceptual Anticipation?. Transplant Cell Ther. 2023 Jan.29(1):65. Pubmedid: 36179988.
      • Zurko J, Ramdial J, Shadman M, Ahmed S, Szabo A, Iovino L, Tomas AA, Sauter C, Perales MA, Shah NN, Acharya UH, Jacobson C, Soiffer RJ, Wang T, Komanduri KV, Jaglowski S, Kittai AS, Denlinger N, Iqbal M, Kharfan-Dabaja MA, Ayala E, Chavez J, Jain M, Locke FL, Samara Y, Budde LE, Mei MG, Pia AD, Feldman T, Ahmed N, Jacobs R, Ghosh N, Dholaria B, Oluwole OO, Hess B, Hassan A, Kenkre VP, Reagan P, Awan F, Nieto Y, Hamadani M, Herrera AF. Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma. Haematologica. 2023 Jan.108(1):98-109. Pubmedid: 35833303. Pmcid: PMC9827150.
      • Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Bouabdallah K, Khanal R, Topp MS, Houot R, Beitinjaneh A, Peng W, Fang X, Shen RR, Siddiqi R, Kloos I, Reagan PM. Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study. J Clin Oncol. 2023 Jan.41(3):555-567. Pubmedid: 35658525. Pmcid: PMC9870225.
      • Choi JW, Dean EA, Lu H, Thompson Z, Qi J, Krivenko G, Jain MD, Locke FL, Balagurunathan Y. Repeatability of metabolic tumor burden and lesion glycolysis between clinical readers. Front Immunol. 2023 Feb.14:994520. Pubmedid: 36875072. Pmcid: PMC9975754.
      • Lee DH, Jain M, Lazaryan A, Locke FL, Jeong D, Alomar M. Case of Myocarditis After Chimeric Antigen Receptor T Cells With Intracardiac Lymphoma. JACC Case Rep. 2023 Feb.8:101634. Pubmedid: 36860560. Pmcid: PMC9969540.
      • Kirtane K, Reblin M, Oswald LB, Irizarry-Arroyo N, McCormick R, Locke FL, Ketcher D. Psychosocial characteristics of patients undergoing cellular immunotherapies and their caregivers across time. Leuk Lymphoma. 2023 Feb.64(2):364-370. Pubmedid: 36416677. Pmcid: PMC10329860.
      • Blue B, Alomar M, Locke FL. Guarding the Heart in an Era of "Tachy-CAR-T": The Rapid Proliferation of a Transformative Therapy. JACC CardioOncol. 2023 Dec.5(6):755-757. Pubmedid: 38204996. Pmcid: PMC10774745.
      • Khaled ML, Ren Y, Kundalia R, Alhaddad H, Chen Z, Wallace GC, Evernden B, Ospina OE, Hall M, Liu M, Darville LNF, Izumi V, Chen YA, Pilon-Thomas S, Stewart PA, Koomen JM, Corallo SA, Jain MD, Robinson TJ, Locke FL, Forsyth PA, Smalley I. Branched-chain keto acids promote an immune-suppressive and neurodegenerative microenvironment in leptomeningeal disease. bioRxiv. 2023 Dec. Pubmedid: 38187773. Pmcid: PMC10769272.
      • Rejeski K, Subklewe M, Locke FL. Recognizing, defining, and managing CAR-T hematologic toxicities. Hematology Am Soc Hematol Educ Program. 2023 Dec.2023(1):198-208. Pubmedid: 38066881. Pmcid: PMC10727074.
      • Johnson GA, Locke FL. Mechanisms of Resistance to Chimeric Antigen Receptor T Cell Therapy. Hematol Oncol Clin North Am. 2023 Dec.37(6):1189-1199. Pubmedid: 37580193.
      • Dean EA, Kimmel GJ, Frank MJ, Bukhari A, Hossain NM, Jain MD, Dahiya S, Miklos DB, Altrock PM, Locke FL. Circulating tumor DNA adds specificity to PET after axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2023 Aug.7(16):4608-4618. Pubmedid: 37126659. Pmcid: PMC10448428.
      • Lee DH, Kumar A, Mohammed T, Peres LC, Alsina M, Bachmeier CA, Blue B, Brayer J, Chandrasekhar S, Grajales-Cruz AF, De Avila G, Elmariah H, Faramand RG, Freeman CL, Jain MD, Khadka S, Khimani F, Liu H, Nishihori T, Oswald LB, Castaneda Puglianini OA, Shain KH, Smith E, Baz RC, Locke FL, Oliveira GH, Alomar M, Hansen DK. Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma. Blood Adv. 2023 Aug.7(16):4247-4257. Pubmedid: 37307173. Pmcid: PMC10424134.
      • Ferreri CJ, Hildebrandt MAT, Hashmi H, Shune LO, McGuirk JP, Sborov DW, Wagner CB, Kocoglu MH, Rapoport A, Atrash S, Voorhees PM, Khouri J, Dima D, Afrough A, Kaur G, Anderson LD, Simmons G, Davis JA, Kalariya N, Peres LC, Lin Y, Janakiram M, Nadeem O, Alsina M, Locke FL, Sidana S, Hansen DK, Patel KK, Castaneda Puglianini OA. Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. Blood Cancer J. 2023 Aug.13(1):117. Pubmedid: 37558706. Pmcid: PMC10412575.
      • Bücklein V, Perez A, Rejeski K, Iacoboni G, Jurinovic V, Holtick U, Penack O, Kharboutli S, Blumenberg V, Ackermann J, Frölich L, Johnson G, Patel K, Arciola B, Mhaskar R, Wood A, Schmidt C, Albanyan O, Gödel P, Hoster E, Bullinger L, Mackensen A, Locke F, von Bergwelt M, Barba P, Subklewe M, Jain MD. Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use. Hemasphere. 2023 Aug.7(8):e907. Pubmedid: 37449196. Pmcid: PMC10337711.
      • Lee DH, Chandrasekhar S, Jain MD, Mhaskar R, Reid K, Lee SB, Corallo S, Hidalgo-Vargas MJ, Kumar A, Chavez J, Shah B, Lazaryan A, Khimani F, Nishihori T, Bachmeier C, Faramand R, Fradley MG, Jeong D, Oliveira GH, Locke FL, Davila ML, Alomar M. Cardiac and inflammatory biomarker differences in adverse cardiac events after chimeric antigen receptor T-Cell therapy: an exploratory study. Cardiooncology. 2023 Apr.9(1):18. Pubmedid: 37005652. Pmcid: PMC10067156.
      • Hansen DK, Sidana S, Peres LC, Colin Leitzinger C, Shune L, Shrewsbury A, Gonzalez R, Sborov DW, Wagner C, Dima D, Hashmi H, Kocoglu MH, Atrash S, Simmons G, Kalariya N, Ferreri C, Afrough A, Kansagra A, Voorhees P, Baz R, Khouri J, Alsina M, McGuirk J, Locke FL, Patel KK. Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium. J Clin Oncol. 2023 Apr.41(11):2087-2097. Pubmedid: 36623248. Pmcid: PMC10082273.
      • Stein-Thoeringer CK, Saini NY, Zamir E, Blumenberg V, Schubert ML, Mor U, Fante MA, Schmidt S, Hayase E, Hayase T, Rohrbach R, Chang CC, McDaniel L, Flores I, Gaiser R, Edinger M, Wolff D, Heidenreich M, Strati P, Nair R, Chihara D, Fayad LE, Ahmed S, Iyer SP, Steiner RE, Jain P, Nastoupil LJ, Westin J, Arora R, Wang ML, Turner J, Menges M, Hidalgo-Vargas M, Reid K, Dreger P, Schmitt A, Müller-Tidow C, Locke FL, Davila ML, Champlin RE, Flowers CR, Shpall EJ, Poeck H, Neelapu SS, Schmitt M, Subklewe M, Jain MD, Jenq RR, Elinav E. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. Nat Med. 2023 Apr.29(4):906-916. Pubmedid: 36914893. Pmcid: PMC10121864.
      • Lee D, Jordan AI, Menges MA, Lazaryan A, Nishihori T, Gaballa SR, Shah BD, Pinilla-Ibarz J, Baluch A, Klinkova OV, Chavez JC, Jain MD, Locke FL. Pneumococcal Conjugate Vaccine Does Not Induce Humoral Response When Administrated Within the Six Months After CD19 CAR T-Cell Therapy. Transplant Cell Ther. 2023 Apr.29(4):277.e1-277.e9. Pubmedid: 35970303.
      • Nikiforow S, Frigault MJ, Frey NV, Gardner RA, Komanduri KV, Perales MA, Kebriaei P, Warkentin PI, Pasquini M, Aho JL, Levine BL, Heslop HE, Hlucky TL, Habucky K, Gharibo M, Jagasia M, Locke FL. Paving the Road for Chimeric Antigen Receptor T Cells: American Society for Transplantation and Cellular Therapy 80/20 Task Force Consensus on Challenges and Solutions to Improving Efficiency of Clinical Center Certification and Maintenance of Operations. Transplant Cell Ther. 2023 Apr.29(4):228-239. Pubmedid: 36709800.
      • Saini NY, Swoboda DM, Greenbaum U, Ma J, Patel RD, Devashish K, Das K, Tanner MR, Strati P, Nair R, Fayad L, Ahmed S, Lee HJ, Iyer SP, Steiner R, Jain N, Nastoupil L, Loghavi S, Tang G, Bassett RL, Jain P, Wang M, Westin JR, Green MR, Sallman DA, Padron E, Davila ML, Locke FL, Champlin RE, Garcia-Manero G, Shpall EJ, Kebriaei P, Flowers CR, Jain MD, Wang F, Futreal AP, Gillis N, Neelapu SS, Takahashi K. Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma. Blood Cancer Discov. 2022 Sep.3(5):385-393. Pubmedid: 35533245. Pmcid: PMC9445749.
      • Jacobson CA, Locke FL, Ma L, Asubonteng J, Hu ZH, Siddiqi T, Ahmed S, Ghobadi A, Miklos DB, Lin Y, Perales MA, Lunning MA, Herr MM, Hill BT, Ganguly S, Dong H, Nikiforow S, Hooper M, Kawashima J, Xu H, Pasquini MC. Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States. Transplant Cell Ther. 2022 Sep.28(9):581.e1-581.e8. Pubmedid: 35609867. Pmcid: PMC9427701.
      • Scholler N, Perbost R, Locke FL, Jain MD, Turcan S, Danan C, Chang EC, Neelapu SS, Miklos DB, Jacobson CA, Lekakis LJ, Lin Y, Ghobadi A, Kim JJ, Chou J, Plaks V, Wang Z, Xue A, Mattie M, Rossi JM, Bot A, Galon J. Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma. Nat Med. 2022 Sep.28(9):1872-1882. Pubmedid: 36038629. Pmcid: PMC9499856.
      • Abraham-Miranda J, Menges M, Atkins R, Mattie M, Kanska J, Turner J, Hidalgo-Vargas MJ, Locke FL. CAR-T manufactured from frozen PBMC yield efficient function with prolonged in vitro production. Front Immunol. 2022 Sep.13:1007042. Pubmedid: 36225930. Pmcid: PMC9549966.
      • Jacobs MT, Jain MD, Gao F, Nastoupil LJ, Spiegel JY, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan PM, Oluwole OO, McGuirk J, Deol A, Sehgal A, Goy A, Hill BT, Andreadis C, Munoz J, Chavez JC, Bennani NN, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Ghobadi A, Locke FL. Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium. Clin Lymphoma Myeloma Leuk. 2022 Oct.22(10):753-759. Pubmedid: 35780055.
      • Ghobadi A, Slade M, Kantarjian HM, Alvarenga J, Aldoss I, Mohammed K, Jabbour EJ, Faramand RG, Shah BD, Locke FL, Fingrut W, Park JH, Short NJ, Gao F, Uy GL, Westervelt P, DiPersio JF, Champlin RE, Al Malki MM, Ravandi F, Kebriaei P. The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis. Blood. 2022 Nov.140(20):2101-2112. Pubmedid: 35877996.
      • Oswald LB, Li X, Carvajal R, Hoogland AI, Gudenkauf LM, Hansen DK, Alsina M, Locke FL, Rodriguez Y, Irizarry-Arroyo N, Robinson EJ, Jim HSL, Gonzalez BD, Kirtane K. Longitudinal Collection of Patient-Reported Outcomes and Activity Data during CAR-T Therapy: Feasibility, Acceptability, and Data Visualization. Cancers (Basel). 2022 May.14(11). Pubmedid: 35681722. Pmcid: PMC9179384.
      • Rejeski K, Perez A, Iacoboni G, Penack O, Bücklein V, Jentzsch L, Mougiakakos D, Johnson G, Arciola B, Carpio C, Blumenberg V, Hoster E, Bullinger L, Locke FL, von Bergwelt-Baildon M, Mackensen A, Bethge W, Barba P, Jain MD, Subklewe M. The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL. J Immunother Cancer. 2022 May.10(5). Pubmedid: 35580927. Pmcid: PMC9114843.
      • Shadman M, Pasquini MC, Ahn KW, Chen Y, Turtle CJ, Hematti P, Cohen JB, Khimani F, Ganguly S, Merryman RW, Yared JA, Locke FL, Ahmed N, Munshi P, Beitinjaneh A, Reagan P, Herrera AF, Sauter CS, Kharfan-Dabaja MA, Hamadani M. Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission. Blood. 2022 Mar.139(9):1330-1339. Pubmedid: 34570879. Pmcid: PMC8900276.
      • Hoogland AI, Barata A, Logue J, Kommalapati A, Hyland KA, Nelson AM, Eisel SL, Small BJ, James BW, Christy SM, Bulls HW, Booth-Jones M, Jayani RV, Jain MD, Mokhtari S, Chavez JC, Lazaryan A, Shah BD, Locke FL, Jim HSL. Change in Neurocognitive Performance Among Patients with Non-Hodgkin Lymphoma in the First Year after Chimeric Antigen Receptor T Cell Therapy. Transplant Cell Ther. 2022 Jun.28(6):305.e1-305.e9. Pubmedid: 35378330. Pmcid: PMC9197947.
      • Cheng R, Scippa K, Locke FL, Snider JT, Jim H. Patient Perspectives on Health-Related Quality of Life in Diffuse Large B-Cell Lymphoma Treated with Car T-Cell Therapy: A Qualitative Study. Oncol Ther. 2022 Jun.10(1):123-141. Pubmedid: 34778941. Pmcid: PMC8590924.
      • Perez A, Johnson G, Patel K, Arciola B, Wood A, Bachmeier CA, Chavez JC, Shah BD, Khimani F, Nishihori T, Lazaryan A, Davila ML, Mhaskar R, Locke FL, Gaballa S, Jain MD. Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL. Blood Adv. 2022 Jul.6(13):3970-3973. Pubmedid: 35816359. Pmcid: PMC9278282.
      • Barata A, Hoogland AI, Kommalapati A, Logue J, Welniak T, Hyland KA, Eisel SL, Small BJ, Jayani RV, Booth-Jones M, Oswald LB, Gonzalez BD, Kirtane KS, Jain MD, Mokhtari S, Chavez JC, Lazaryan A, Shah BD, Locke FL, Jim HSL. Change in Patients' Perceived Cognition Following Chimeric Antigen Receptor T-Cell Therapy for Lymphoma. Transplant Cell Ther. 2022 Jul.28(7):401.e1-401.e7. Pubmedid: 35580732. Pmcid: PMC9339228.
      • Lazaryan A, Lee SJ, Arora M, Kim J, Betts BC, Khimani F, Nishihori T, Bejanyan N, Liu H, Kharfan-Dabaja MA, Locke FL, Gonzalez R, Jain MD, Davila ML, Perez LE, Mishra A, Perez Perez A, Balke K, Ayala E, Ochoa L, Castaneda Puglianini O, Faramand RG, Alsina M, Elmariah H, Nieder M, Fernandez H, Anasetti C, Pidala J. A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease. Blood Adv. 2022 Jan.6(1):259-269. Pubmedid: 34649279. Pmcid: PMC8753213.
      • Hamadani M, Gopal AK, Pasquini MC, Kim S, Qiu X, Ahmed S, Lazaryan A, Bhatt VR, Daly A, Lulla P, Ciurea SO, Gauthier J, Agrawal V, Grover NS, Lekakis LJ, Modi D, Dahi PB, Herr MM, Johnson PC, Hashmi H, Hematti P, Locke FL. Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis. Blood Adv. 2022 Jan.6(2):486-494. Pubmedid: 34673903. Pmcid: PMC8791562.
      • Oluwole OO, Liu R, Diakite I, Feng C, Patel A, Nourhussein I, Snider JT, Locke FL. Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US. J Med Econ. 2022 Jan.25(1):541-551. Pubmedid: 35443867.
      • Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, Ghobadi A, Rapoport AP, McGuirk J, Pagel JM, Muñoz J, Farooq U, van Meerten T, Reagan PM, Sureda A, Flinn IW, Vandenberghe P, Song KW, Dickinson M, Minnema MC, Riedell PA, Leslie LA, Chaganti S, Yang Y, Filosto S, Shah J, Schupp M, To C, Cheng P, Gordon LI, Westin JR. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med. 2022 Feb.386(7):640-654. Pubmedid: 34891224.
      • Kimmel GJ, Locke FL, Altrock PM. Correction to 'The roles of T-cell competition and stochastic extinction events in CAR T-cell therapy'. Proc Biol Sci. 2022 Feb.289(1968):20212786. Pubmedid: 35135356. Pmcid: PMC8826130.
      • Sheikh S, Mokhtari S, Silverman JA, Reid K, Faramand R, Davila ML, Franke N, Locke FL, Jain MD, Wong D, Kuruvilla JG. Transverse myelitis after anti-CD19 directed CAR T cell therapy for relapsed large B cell lymphoma. EJHaem. 2022 Feb.3(1):223-227. Pubmedid: 35846190. Pmcid: PMC9175700.
      • Wood AC, Perez AP, Arciola B, Patel K, Johnson G, DiMaggio E, Bachmeier CA, Reid K, Carallo S, Vargas MH, Faramand R, Chavez JC, Shah B, Gaballa S, Khimani F, Elmariah H, Nishihori T, Lazaryan A, Freeman C, Davila ML, Locke FL, Mhaskar R, Bassil C, Jain MD. Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis. Transplant Cell Ther. 2022 Dec.28(12):829.e1-829.e8. Pubmedid: 36174934. Pmcid: PMC9791940.
      • Logue JM, Peres LC, Hashmi H, Colin-Leitzinger C, Shrewsbury AM, Hosoya H, Gonzalez R, Copponex C, Kottra KH, Hovanky V, Sahaf B, Patil S, Lazaryan A, Jain MD, Baluch A, Klinkova O, Bejanyan N, Faramand RG, Elmariah H, Khimani F, Davila ML, Mishra A, Blue B, Grajales-Cruz AF, Castaneda Puglianini O, Liu H, Nishihori T, Freeman CL, Brayer J, Shain KH, Baz R, Locke FL, Alsina M, Sidana S, Hansen DK. Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma. Blood Adv. 2022 Dec.6(24):6109-6119. Pubmedid: 35939783. Pmcid: PMC9768247.
      • Oluwole OO, Chen JMH, Chan K, Patel AR, Jansen JP, Keeping S, Zheng Y, Snider JT, Locke FL. Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphoma. Leuk Lymphoma. 2022 Dec.63(13):3052-3062. Pubmedid: 36048026.
      • Jain MD, Ziccheddu B, Coughlin CA, Faramand RG, Griswold AJ, Reid KM, Menges M, Zhang Y, Cen L, Wang X, Hussaini MO, Landgren O, Davila ML, Schatz JH, Locke FL, Maura F. Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma. Blood. 2022 Aug.140(5):491-503. Pubmedid: 35476848. Pmcid: PMC9353150.
      • Eriksen-Gjerstad M, Tveit Karlsen I, Fandalyuk Z, Benjaminsen S, Baran-Marszak F, Papp B, Locke F, Ladds M, Pastor-Fernández A, Gelebart P, Mc Cormack E. Dihydroorotate dehydrogenase inhibition acts synergistically with tyrosine kinase inhibitors to induce apoptosis of mantle cell lymphoma cells. EJHaem. 2022 Aug.3(3):913-918. Pubmedid: 36051066. Pmcid: PMC9422018.
      • Munshi PN, Chen Y, Ahn KW, Awan FT, Cashen A, Shouse G, Shadman M, Shaughnessy P, Zurko J, Locke FL, Goodman AM, Bisneto JCV, Sauter C, Kharfan-Dabaja MA, Meyers G, Jaglowski S, Herrera A. Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B-Cell Lymphoma. Transplant Cell Ther. 2022 Aug.28(8):487.e1-487.e7. Pubmedid: 35609865. Pmcid: PMC9375438.
      • Cortes A, Perez A, Bachmeier C, Mhaskar R, Chavez JC, Shah B, Nishihori T, Khimani F, Lazaryan A, Davila ML, Locke FL, Jain MD. Outcomes of CD19 Chimeric Antigen Receptor T Cell Therapy in Patients with Gastrointestinal Tract Involvement of Large B Cell Lymphoma. Transplant Cell Ther. 2021 Sep.27(9):768.e1-768.e6. Pubmedid: 34077811. Pmcid: PMC8403629.
      • Plaks V, Rossi JM, Chou J, Wang L, Poddar S, Han G, Wang Z, Kuang SQ, Chu F, Davis RE, Vega F, Bashir Z, Jacobson CA, Locke FL, Reagan P, Rodig SJ, Lekakis LJ, Flinn IW, Miklos DB, Bot A, Neelapu SS. CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel. Blood. 2021 Sep.138(12):1081-1085. Pubmedid: 34041526. Pmcid: PMC8462361.
      • Frank MJ, Hossain NM, Bukhari A, Dean E, Spiegel JY, Claire GK, Kirsch I, Jacob AP, Mullins CD, Lee LW, Kong KA, Craig J, Mackall CL, Rapoport AP, Jain MD, Dahiya S, Locke FL, Miklos DB. Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial. J Clin Oncol. 2021 Sep.39(27):3034-3043. Pubmedid: 34133196.
      • Munshi PN, Hamadani M, Kumar A, Dreger P, Friedberg JW, Dreyling M, Kahl B, Jerkeman M, Kharfan-Dabaja MA, Locke FL, Shadman M, Hill BT, Ahmed S, Herrera AF, Sauter CS, Bachanova V, Ghosh N, Lunning M, Kenkre VP, Aljurf M, Wang M, Maddocks KJ, Leonard JP, Kamdar M, Phillips T, Cashen AF, Inwards DJ, Sureda A, Cohen JB, Smith SM, Carlo-Stella C, Savani B, Robinson SP, Fenske TS. American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies. Transplant Cell Ther. 2021 Sep.27(9):720-728. Pubmedid: 34452722. Pmcid: PMC8447221.
      • Roselli E, Boucher JC, Li G, Kotani H, Spitler K, Reid K, Cervantes EV, Bulliard Y, Tu N, Lee SB, Yu B, Locke FL, Davila ML. 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells. J Immunother Cancer. 2021 Oct.9(10). Pubmedid: 34706886. Pmcid: PMC8552146.
      • Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Reagan P, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Crump M, Kuruvilla J, Van Den Neste EW, Farooq U, Navale L, DePuy V, Kim JJ, Gisselbrecht C. Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma. Blood Adv. 2021 Oct.5(20):4149-4155. Pubmedid: 34478487. Pmcid: PMC8945634.
      • Westin JR, Kersten MJ, Salles G, Abramson JS, Schuster SJ, Locke FL, Andreadis C. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials. Am J Hematol. 2021 Oct.96(10):1295-1312. Pubmedid: 34310745. Pmcid: PMC9290945.
      • Khimani F, Ranspach P, Elmariah H, Kim J, Whiting J, Nishihori T, Locke FL, Perez Perez A, Dean E, Mishra A, Perez L, Lazaryan A, Jain MD, Nieder M, Liu H, Faramand R, Hansen D, Alsina M, Ochoa L, Davila M, Anasetti C, Pidala J, Bejanyan N. Increased Infections and Delayed CD4+ T Cell but Faster B Cell Immune Reconstitution after Post-Transplantation Cyclophosphamide Compared to Conventional GVHD Prophylaxis in Allogeneic Transplantation. Transplant Cell Ther. 2021 Nov.27(11):940-948. Pubmedid: 34329754.
      • Jain MD, Locke FL. Seeing the Light: CAR T-cell Targeting of Lambda-restricted B-cell Lymphomas. Clin Cancer Res. 2021 Nov.27(21):5736-5738. Pubmedid: 34417197.
      • Heslop HE, Stadtmauer EA, Levine JE, Ballen KK, Chen YB, DeZern AE, Eapen M, Hamadani M, Hamilton BK, Hari P, Jones RJ, Logan BR, Kean LS, Leifer ES, Locke FL, Maziarz RT, Nemecek ER, Pasquini M, Phelan R, Riches ML, Shaw BE, Walters MC, Foley A, Devine SM, Horowitz MM. Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year. Transplant Cell Ther. 2021 Nov.27(11):885-907. Pubmedid: 34461278. Pmcid: PMC8556300.
      • Riedell PA, Hamadani M, Ahn KW, Litovich C, Murthy GSG, Locke FL, Brunstein CG, Merryman RW, Stiff PJ, Pawarode A, Nishihori T, Kharfan-Dabaja MA, Herrera AF, Sauter CS, Smith SM. Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell Lymphoma. Transplant Cell Ther. 2021 Nov.27(11):911.e1-911.e7. Pubmedid: 34450333. Pmcid: PMC8556305.
      • Jain MD, Zhao H, Wang X, Atkins R, Menges M, Reid K, Spitler K, Faramand R, Bachmeier CA, Dean EA, Cao B, Chavez JC, Shah BD, Lazaryan A, Nishihori T, Hussaini MO, Gonzalez RJ, Mullinax JE, Rodriguez P, Conejo-Garcia J, Anasetti C, Davila ML, Locke FL. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. Blood. 2021 May.137(19):2621-2633. Pubmedid: 33512407. Pmcid: PMC8120145.
      • Hoogland AI, Jayani RV, Collier A, Irizarry-Arroyo N, Rodriguez Y, Jain MD, Booth-Jones M, Hyland KA, James BW, Barata A, Bachmeier CA, Chavez JC, Khimani F, Krivenko GS, Lazaryan A, Liu HD, Nishihori T, Pinilla-Ibarz J, Shah BD, Abidi M, Locke FL, Jim HSL. Acute patient-reported outcomes in B-cell malignancies treated with axicabtagene ciloleucel. Cancer Med. 2021 Mar.10(6):1936-1943. Pubmedid: 33641257. Pmcid: PMC7957158.
      • Kimmel GJ, Locke FL, Altrock PM. The roles of T cell competition and stochastic extinction events in chimeric antigen receptor T cell therapy. Proc Biol Sci. 2021 Mar.288(1947):20210229. Pubmedid: 33757357. Pmcid: PMC8059581.
      • Bejanyan N, Pidala JA, Wang X, Thapa R, Nishihori T, Elmariah H, Lazaryan A, Khimani F, Davila ML, Mishra A, Faramand R, Jain MD, Ochoa L, Perez LE, Liu H, Alsina M, Kharfan-Dabaja MA, Fernandez H, Nieder ML, Locke FL, Anasetti C, Ayala E. A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation. Blood Adv. 2021 Mar.5(5):1154-1163. Pubmedid: 33635333. Pmcid: PMC7948297.
      • Mirza AS, Kumar A, Hashmi H, Garcia F, Logothetis CN, Darwin A, Faramand R, Reid K, Bachmeier C, Chavez JC, Shah B, Pinilla-Ibarz J, Khimani F, Lazaryan A, Liu H, Davila ML, Nishihori T, Locke FL, Jain MD. Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell Lymphoma. Transplant Cell Ther. 2021 Mar.27(3):242.e1-242.e6. Pubmedid: 33781520.
      • Cornell RF, Bishop MR, Kumar S, Giralt SA, Nooka AK, Larson SM, Locke FL, Raje NS, Lei L, Dong J, Le Gall JB, Rossi JM, Orlowski RZ. A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma. Am J Cancer Res. 2021 Jun.11(6):3285-3293. Pubmedid: 34249462. Pmcid: PMC8263642.
      • Khimani F, Dutta M, Faramand R, Nishihori T, Perez AP, Dean E, Nieder M, Perez L, Mishra A, Elmariah H, Davila M, Ochoa L, Alsina M, Lazaryan A, Bejanyan N, Hansen D, Jain M, Locke F, Liu H, Pidala J, Shah B, Mhaskar R. Impact of Total Body Irradiation-Based Myeloablative Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Systematic Review and Meta-Analysis. Transplant Cell Ther. 2021 Jul.27(7):620.e1-620.e9. Pubmedid: 33798768.
      • Perez L, Fernandez H, Kharfan-Dabaja M, Khimani F, Betts B, Mishra A, Ayala E, Locke FL, Ochoa-Bayona L, Nieder M, Pidala J, Achille A, Powers J, Sahakian E, Thapa R, Wang X, Anasetti C. A phase 2 trial of the histone deacetylase inhibitor panobinostat for graft-versus-host disease prevention. Blood Adv. 2021 Jul.5(13):2740-2750. Pubmedid: 34242388. Pmcid: PMC8288668.
      • Guerrouahen B, Elnaggar M, Al-Mohannadi A, Kizhakayil D, Bonini C, Benjamin R, Brentjens R, Buchholz CJ, Casorati G, Ferrone S, Locke FL, Martin F, Schambach A, Turtle C, Veys P, van der Vliet HJ, Maccalli C. Proceedings From the First International Workshop at Sidra Medicine: "Engineered Immune Cells in Cancer Immunotherapy (EICCI): From Discovery to Off-the-Shelf Development", 15th-16th February 2019, Doha, Qatar. Front Immunol. 2021 Jan.11:589381. Pubmedid: 33584653. Pmcid: PMC7874217.
      • Liu R, Oluwole OO, Diakite I, Botteman MF, Snider JT, Locke FL. Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States. J Med Econ. 2021 Jan.24(1):458-468. Pubmedid: 33691581.
      • Mishra A, Pidala J, Thapa R, Betts BC, Fernandez H, Locke FL, Nishihori T, Perez L, Wang X, Anasetti C, Jim H. Objective and subjective physical function in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2021 Dec.56(12):2897-2903. Pubmedid: 34381169.
      • Figura NB, Robinson TJ, Sim AJ, Wang X, Cao B, Chavez JC, Shah BD, Khimani F, Lazaryan A, Davila M, Bachmeier C, Nishihori T, Liu HD, Kim S, Locke FL, Jain MD. Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell Therapy. Int J Radiat Oncol Biol Phys. 2021 Dec.111(5):1145-1154. Pubmedid: 34242714. Pmcid: PMC9791939.
      • Munshi PN, Hamadani M, Kumar A, Dreger P, Friedberg JW, Dreyling M, Kahl B, Jerkeman M, Kharfan-Dabaja MA, Locke FL, Shadman M, Hill BT, Ahmed S, Herrera AF, Sauter CS, Bachanova V, Ghosh N, Lunning M, Kenkre VP, Aljurf M, Wang M, Maddocks KJ, Leonard JP, Kamdar M, Phillips T, Cashen AF, Inwards DJ, Sureda A, Cohen JB, Smith SM, Carlo-Stella C, Savani B, Robinson SP, Fenske TS. ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. Bone Marrow Transplant. 2021 Dec.56(12):2911-2921. Pubmedid: 34413469. Pmcid: PMC8639670.
      • Rejeski K, Perez Perez A, Sesques P, Hoster E, Berger CS, Jentzsch L, Mougiakakos D, Frölich L, Ackermann J, Buecklein V, Blumenberg V, Schmidt C, Jallades L, Fehse B, Faul C, Karschnia P, Weigert O, Dreyling M, Locke FL, von Bergwelt-Baildon M, Mackensen A, Bethge WA, Ayuk F, Bachy E, Salles GA, Jain MD, Subklewe M. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma. Blood. 2021 Dec.138(24):2499-2513. Pubmedid: 34166502. Pmcid: PMC8893508.
      • Barata A, Hoogland AI, Hyland KA, Otto AK, Kommalapati A, Jayani RV, Irizarry-Arroyo N, Collier A, Rodriguez Y, Welniak TL, Booth-Jones M, Logue J, Small BJ, Jain MD, Reblin M, Locke FL, Jim HSL. Quality of life in caregivers of patients receiving chimeric antigen receptor T-cell therapy. Psychooncology. 2021 Aug.30(8):1294-1301. Pubmedid: 33739548. Pmcid: PMC9828891.
      • Logue JM, Zucchetti E, Bachmeier CA, Krivenko GS, Larson V, Ninh D, Grillo G, Cao B, Kim J, Chavez JC, Baluch A, Khimani F, Lazaryan A, Nishihori T, Liu HD, Pinilla-Ibarz J, Shah BD, Faramand R, Coghill AE, Davila ML, Dholaria BR, Jain MD, Locke FL. Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma. Haematologica. 2021 Apr.106(4):978-986. Pubmedid: 32327504. Pmcid: PMC8017820.
      • Spiegel JY, Dahiya S, Jain MD, Tamaresis JS, Nastoupil L, Jacobs MT, Ghobadi A, Lin Y, Lunning M, Lekakis LJ, Reagan P, Oluwole OO, McGuirk JP, Deol A, Goy A, Vu K, Andreadis C, Munoz J, Bennani NN, Vose J, Dorritie KA, Neelapu SS, Locke FL, Rapoport AP, Hill B, Miklos DB. Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy. Blood. 2021 Apr.137(13):1832-1835. Pubmedid: 33156925. Pmcid: PMC8555382.
      • Locke FL. Chimeric Antigen Receptor T Cell Therapy Delivers Response in Lymphoma Progressing after Allogeneic Transplantation, but is the Sequence Optimal?. Biol Blood Marrow Tr. 2020 Sep.26(9):e211-e212. Pubmedid: 32682950.
      • Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Sehgal AR, Goy A, Hill BT, Vu K, Andreadis C, Munoz J, Westin J, Chavez JC, Cashen A, Bennani NN, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Locke FL. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. J Clin Oncol. 2020 Sep.38(27):3119-3128. Pubmedid: 32401634. Pmcid: PMC7499611.
      • Faramand R, Jain M, Staedtke V, Kotani H, Bai R, Reid K, Lee SB, Spitler K, Wang X, Cao B, Pinilla J, Lazaryan A, Khimani F, Shah B, Chavez JC, Nishihori T, Mishra A, Mullinax J, Gonzalez R, Hussaini M, Dam M, Brandjes BD, Bachmeier CA, Anasetti C, Locke FL, Davila ML. Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel. Clin Cancer Res. 2020 Sep.26(18):4823-4831. Pubmedid: 32669372. Pmcid: PMC7501265.
      • Hashmi H, Mirza AS, Darwin A, Logothetis C, Garcia F, Kommalapati A, Mhaskar RS, Bachmeier C, Chavez JC, Shah B, Pinilla-Ibarz J, Khimani F, Lazaryan A, Liu H, Davila ML, Locke FL, Nishihori T, Jain MD. Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma. Blood Adv. 2020 Sep.4(17):4086-4090. Pubmedid: 32877523. Pmcid: PMC7479945.
      • Oluwole OO, Jansen JP, Lin VW, Chan K, Keeping S, Navale L, Locke FL. Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma. Biol Blood Marrow Tr. 2020 Sep.26(9):1581-1588. Pubmedid: 32561336.
      • Locke FL, Rossi JM, Neelapu SS, Jacobson CA, Miklos DB, Ghobadi A, Oluwole OO, Reagan PM, Lekakis LJ, Lin Y, Sherman M, Better M, Go WY, Wiezorek JS, Xue A, Bot A. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020 Oct.4(19):4898-4911. Pubmedid: 33035333. Pmcid: PMC7556133.
      • Pasquini MC, Hu ZH, Curran K, Laetsch T, Locke F, Rouce R, Pulsipher MA, Phillips CL, Keating A, Frigault MJ, Salzberg D, Jaglowski S, Sasine JP, Rosenthal J, Ghosh M, Landsburg D, Margossian S, Martin PL, Kamdar MK, Hematti P, Nikiforow S, Turtle C, Perales MA, Steinert P, Horowitz MM, Moskop A, Pacaud L, Yi L, Chawla R, Bleickardt E, Grupp S. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020 Nov.4(21):5414-5424. Pubmedid: 33147337. Pmcid: PMC7656920.
      • Alvi RM, Fradley MG, Frigault MJ, Locke FL, Neilan TG. Reply: Cardiac Events Associated With Chimeric Antigen Receptor T Cells (CAR-T): A VigiBase Perspective. J Am Coll Cardiol. 2020 May.75(19):2523-2524. Pubmedid: 32408985.
      • Neelapu SS, Jacobson CA, Oluwole OO, Munoz J, Deol A, Miklos D, Bartlett NL, Braunschweig I, Jiang Y, Kim JJ, Zheng L, Rossi JM, Locke FL. Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2020 Jun.135(23):2106-2109. Pubmedid: 32181801. Pmcid: PMC7273828.
      • Davids MS, Kim HT, Costello C, Herrera AF, Locke FL, Maegawa RO, Savell A, Mazzeo M, Anderson A, Boardman AP, Weber A, Avigan D, Chen YB, Nikiforow S, Ho VT, Cutler C, Alyea E, Bachireddy P, Wu CJ, Ritz J, Streicher H, Ball ED, Bashey A, Soiffer RJ, Armand P. A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. Blood. 2020 Jun.135(24):2182-2191. Pubmedid: 32478814. Pmcid: PMC7290092.
      • Dean EA, Mhaskar RS, Lu H, Mousa MS, Krivenko GS, Lazaryan A, Bachmeier CA, Chavez JC, Nishihori T, Davila ML, Khimani F, Liu HD, Pinilla-Ibarz J, Shah BD, Jain MD, Balagurunathan Y, Locke FL. High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020 Jul.4(14):3268-3276. Pubmedid: 32702097. Pmcid: PMC7391155.
      • Frairia C, Nicolosi M, Shapiro J, Kim J, Betts BC, Fernandez HF, Locke FL, Mishra A, Nishihori T, Ochoa-Bayona JL, Perez L, Pidala J, Anasetti C. Sole Upfront Therapy with Beclomethasone and Budesonide for Upper Gastrointestinal Acute Graft-versus-Host Disease. Biol Blood Marrow Tr. 2020 Jul.26(7):1303-1311. Pubmedid: 32361010. Pmcid: PMC7771266.
      • Locke FL, Go WY, Neelapu SS. Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma: A Review. JAMA Oncol. 2020 Feb.6(2):281-290. Pubmedid: 31697310. Pmcid: PMC7859915.
      • Maus MV, Alexander S, Bishop MR, Brudno JN, Callahan C, Davila ML, Diamonte C, Dietrich J, Fitzgerald JC, Frigault MJ, Fry TJ, Holter-Chakrabarty JL, Komanduri KV, Lee DW, Locke FL, Maude SL, McCarthy PL, Mead E, Neelapu SS, Neilan TG, Santomasso BD, Shpall EJ, Teachey DT, Turtle CJ, Whitehead T, Grupp SA. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. J Immunother Cancer. 2020 Dec.8(2). Pubmedid: 33335028. Pmcid: PMC7745688.
      • Oluwole OO, Jansen JP, Lin VW, Chan K, Keeping S, Navale L, Locke FL. Response to Letter to Editor Regarding "Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma". Biol Blood Marrow Tr. 2020 Dec.26(12):e335-e336. Pubmedid: 32950694.
      • Schuster SJ, Maziarz RT, Rusch ES, Li J, Signorovitch JE, Romanov VV, Locke FL, Maloney DG. Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial. Blood Adv. 2020 Apr.4(7):1432-1439. Pubmedid: 32271899. Pmcid: PMC7160283.
      • Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Milpied N, Fung H, Topp MS, Houot R, Beitinjaneh A, Peng W, Zheng L, Rossi JM, Jain RK, Rao AV, Reagan PM. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med. 2020 Apr.382(14):1331-1342. Pubmedid: 32242358. Pmcid: PMC7731441.
      • Maziarz RT, Schuster SJ, Romanov VV, Rusch ES, Li J, Signorovitch JE, Maloney DG, Locke FL. Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial. Blood Adv. 2020 Apr.4(7):1440-1447. Pubmedid: 32271898. Pmcid: PMC7160265.
      • Kharfan-Dabaja MA, Jain MD, Aulakh S, Ayala E, Zubair AC, Tun HW, Liu HD, Locke FL, Chavez JC. Obinutuzumab as bridging therapy for successful manufacturing of axicabtagene ciloleucel for transformed follicular lymphoma with circulating cells. Am J Hematol. 2019 Sep.94(9):E245-E247. Pubmedid: 31211433. Pmcid: PMC6917994.
      • Hashmi H, Bachmeier C, Chavez JC, Song J, Hussaini M, Krivenko G, Nishihori T, Kotani H, Davila ML, Locke FL, Jain MD. Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy. Brit J Haematol. 2019 Oct.187(2):e35-e38. Pubmedid: 31410842.
      • Byrne M, Oluwole OO, Savani B, Majhail NS, Hill BT, Locke FL. Understanding and Managing Large B Cell Lymphoma Relapses after Chimeric Antigen Receptor T Cell Therapy. Biol Blood Marrow Tr. 2019 Nov.25(11):e344-e351. Pubmedid: 31279751. Pmcid: PMC7800228.
      • Locke FL. Highlights in CAR T-Cell Therapy in Lymphoma From the 60th American Society of Hematology Annual Meeting: Commentary. Clin Adv Hematol Oncol. 2019 May.17 Suppl 10(5):20-23. Pubmedid: 32720926.
      • Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, Budde LE, Costa L, Davies M, Dunnington D, Ernstoff MS, Frigault M, Hoffner B, Hoimes CJ, Lacouture M, Locke F, Lunning M, Mohindra NA, Naidoo J, Olszanski AJ, Oluwole O, Patel SP, Reddy S, Ryder M, Santomasso B, Shofer S, Sosman JA, Wahidi M, Wang Y, Johnson-Chilla A, Scavone JL. Management of Immunotherapy-Related Toxicities, Version 1.2019. J Natl Compr Canc Ne. 2019 Mar.17(3):255-289. Pubmedid: 30865922.
      • Khimani F, McDonald GB, Shulman HM, Betts B, Locke F, Fernandez H, Anasetti C, Pidala J. Hepatic veno-occlusive disease following sirolimus-based immune suppression. Bone Marrow Transplant. 2019 Jan.54(1):85-89. Pubmedid: 29895929.
      • Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy A, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Wiezorek JS, Navale L, Xue A, Jiang Y, Bot A, Rossi JM, Kim JJ, Go WY, Neelapu SS. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019 Jan.20(1):31-42. Pubmedid: 30518502. Pmcid: PMC6733402.
      • Dholaria BR, Bachmeier CA, Locke F. Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities. BioDrugs. 2019 Feb.33(1):45-60. Pubmedid: 30560413. Pmcid: PMC6733400.
      • Alvi RM, Frigault MJ, Fradley MG, Jain MD, Mahmood SS, Awadalla M, Lee DH, Zlotoff DA, Zhang L, Drobni ZD, Hassan MZO, Bassily E, Rhea I, Ismail-Khan R, Mulligan CP, Banerji D, Lazaryan A, Shah BD, Rokicki A, Raje N, Chavez JC, Abramson J, Locke FL, Neilan TG. Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T). J Am Coll Cardiol. 2019 Dec.74(25):3099-3108. Pubmedid: 31856966. Pmcid: PMC6938409.
      • Sim AJ, Jain MD, Figura N, Chavez JC, Shah BD, Khimani F, Lazarayan A, Krivenko G, Davila ML, Liu HD, Falchook AD, Dahiya S, Rapoport AP, Kim SU, Locke FL, Robinson TJ. Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma. Int J Radiat Oncol Biol Phys. 2019 Dec.105(5):1012-1021. Pubmedid: 31175906. Pmcid: PMC6872916.
      • Ruella M, Locke FL. Beat pediatric ALL MRD: CD28 CAR T and transplant. Blood. 2019 Dec.134(26):2333-2335. Pubmedid: 31877213. Pmcid: PMC6933292.
      • Gopalakrishnan S, D'Souza A, Scott E, Fraser R, Davila O, Shah N, Gale RP, Kamble R, Diaz MA, Lazarus HM, Savani BN, Hildebrandt GC, Solh M, Freytes CO, Lee C, Kyle RA, Usmani SZ, Ganguly S, Assal A, Berdeja J, Kanate AS, Dhakal B, Meehan K, Kindwall-Keller T, Saad A, Locke F, Seo S, Nishihori T, Gergis U, Gasparetto C, Mark T, Nieto Y, Kumar S, Hari P. Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after autologous transplantation for newly diagnosed multiple myeloma. biol blood marrow tr. 2019 apr.25(4):683-688. pubmedid:>30579965. Pmcid: PMC6453717.
      • Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S, Go WY, Eldjerou L, Gardner RA, Frey N, Curran KJ, Peggs K, Pasquini M, DiPersio JF, van den Brink MRM, Komanduri KV, Grupp SA, Neelapu SS. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Tr. 2019 Apr.25(4):625-638. Pubmedid: 30592986.
      • Perez L, Fernandez H, Horna P, Riches M, Locke F, Field T, Powers J, Sahakian E, Villagra A, Mishra A, Betts B, Kharfan-Dabaja M, Beato F, Ochoa-Bayona L, Pidala J, Anasetti C. Phase I trial of histone deacetylase inhibitor panobinostat in addition to glucocorticoids for primary therapy of acute graft-versus-host disease. Bone Marrow Transplant. 2018 Nov.53(11):1434-1444. Pubmedid: 29670210. Pmcid: PMC7771280.
      • Pidala J, Beato F, Kim J, Betts B, Jim H, Sagatys E, Levine JE, Ferrara JL, Ozbek U, Ayala E, Davila M, Fernandez HF, Field T, Kharfan-Dabaja MA, Khaira D, Khimani F, Locke FL, Mishra A, Nieder M, Nishihori T, Perez L, Riches M, Anasetti C. IL-12/IL-23p40 neutralization blocks Th1/Th17 response after allogeneic hematopoietic cell transplantation. Haematologica. 2018 Mar.103(3):531-539. Pubmedid: 29242294. Pmcid: PMC5830373.
      • Chavez JC, Locke FL. CAR T cell therapy for B-cell lymphomas. Best Pract Res Clin Haematol. 2018 Jun.31(2):135-146. Pubmedid: 29909914. Pmcid: PMC6716161.
      • Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, Westin J, Gulbis AM, Loghin ME, de Groot JF, Adkins S, Davis SE, Rezvani K, Hwu P, Shpall EJ. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018 Jan.15(1):47-62. Pubmedid: 28925994. Pmcid: PMC6733403.
      • Locke FL, Anasetti C. Off-the-shelf TCR for graft-versus-leukemia without GVHD. Blood. 2018 Jan.131(1):5-7. Pubmedid: 29301771. Pmcid: PMC5755047.
      • Kharfan-Dabaja MA, Kumar A, Stingo FE, Khimani F, Hussaini M, Ayala E, Nishihori T, Shah B, Locke FL, Pinilla-Ibarz J, Chavez JC. Allogeneic Hematopoietic Cell Transplantation for Richter Syndrome: A Single-Center Experience. Clin Lymphoma Myeloma Leuk. 2018 Jan.18(1):e35-e39. Pubmedid: 29126867. Pmcid: PMC6716154.
      • Murthy HS, Sheets K, Kumar A, Nishihori T, Mina A, Chavez JC, Ayala E, Field T, Mathews J, Locke F, Perez L, Betts BC, Khimani F, Miladinovic B, Tsalatsanis A, Ochoa-Bayona JL, Alsina M, Fernandez H, Pidala J, Anasetti C, Kharfan-Dabaja MA. Hypoalbuminemia at Day +90 Is Associated with Inferior Nonrelapse Mortality and Overall Survival in Allogeneic Hematopoietic Cell Transplantation Recipients: A Confirmatory Study. Biol Blood Marrow Tr. 2018 Feb.24(2):400-405. Pubmedid: 29032266.
      • Locke FL, Haroun F. Advances in aggressive lymphoma from the 2017 American Society of Hematology Annual Meeting and Exposition: commentary. Clin Adv Hematol Oncol. 2018 Feb.16 Suppl 5(2):19-23. Pubmedid: 29742098.
      • Betts BC, Locke FL, Sagatys EM, Pidala J, Walton K, Menges M, Reff J, Saha A, Djeu JY, Kiluk JV, Lee MC, Kim J, Kang CW, Tang CA, Frieling J, Lynch CC, List A, Rodriguez PC, Blazar BR, Conejo-Garcia JR, Del Valle JR, Hu CA, Anasetti C. Inhibition of Human Dendritic Cell ER Stress Response Reduces T Cell Alloreactivity Yet Spares Donor Anti-tumor Immunity. Front Immunol. 2018 Dec.9:2887. Pubmedid: 30574153. Pmcid: PMC6291501.
      • Locke FL, Jain MD. Advances in aggressive lymphoma from the 2018 American Society of Clinical Oncology annual meeting: commentary. Clin Adv Hematol Oncol. 2018 Aug.16 Suppl 14(8):20-23. Pubmedid: 30300338.
      • Hampras SS, Locke FL, Chavez JC, Patel NS, Giuliano AR, Miller K, Gheit T, Tommasino M, Rollison DE. Prevalence of cutaneous viral infections in incident cutaneous squamous cell carcinoma detected among chronic lymphocytic leukemia and hematopoietic stem cell transplant patients. Leuk Lymphoma. 2018 Apr.59(4):911-917. Pubmedid: 28679298. Pmcid: PMC6150603.
      • Neelapu SS, Tummala S, Kebriaei P, Wierda W, Locke FL, Lin Y, Jain N, Daver N, Gulbis AM, Adkins S, Rezvani K, Hwu P, Shpall EJ. Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nat Rev Clin Oncol. 2018 Apr.15(4):218. Pubmedid: 29434334. Pmcid: PMC6716606.
      • Neelapu SS, Locke FL, Go WY. CAR T-Cell Therapy in Large B-Cell Lymphoma. N Engl J Med. 2018 03.378(11):1065. Pubmedid: 29539277.
      • Chavez J, Locke FL. A Possible Cure for Refractory DLBCL: CARs Are Headed in the Right Direction. Mol Ther. 2017 Oct.25(10):2241-2243. Pubmedid: 28941574. Pmcid: PMC5628929.
      • Betts BC, Pidala J, Kim J, Mishra A, Nishihori T, Perez L, Ochoa-Bayona JL, Khimani F, Walton K, Bookout R, Nieder M, Khaira DK, Davila M, Alsina M, Field T, Ayala E, Locke FL, Riches M, Kharfan-Dabaja M, Fernandez H, Anasetti C. IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation. Haematologica. 2017 May.102(5):948-957. Pubmedid: 28104702. Pmcid: PMC5477614.
      • Locke FL, Pidala J, Storer B, Martin PJ, Pulsipher MA, Chauncey TR, Jacobsen N, Kröger N, Walker I, Light S, Shaw BE, Beato F, Laport GG, Nademanee A, Keating A, Socie G, Anasetti C. CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Tr. 2017 Mar.23(3):405-411. Pubmedid: 28007665. Pmcid: PMC6716167.
      • Locke FL, Davila ML. Regulatory challenges and considerations for the clinical application of CAR-T cell anti-cancer therapy. Expert Opin Biol Ther. 2017 Jun.17(6):659-661. Pubmedid: 28454503.
      • Khimani F, Kim J, Chen L, Dean E, Rizk V, Betts B, Nishihori T, Locke F, Mishra A, Perez L, Ayala E, Kharfan-Dabaja M, Nieder M, Fernandez H, Anasetti C, Pidala J. Predictors of overall survival among patients treated with sirolimus/tacrolimus vs methotrexate/tacrolimus for GvHD prevention. Bone Marrow Transplant. 2017 Jul.52(7):1003-1009. Pubmedid: 28368376. Pmcid: PMC7771296.
      • Locke FL, Anasetti C. Transplanters drive CARs to the clinic by brewing ICE-T: the Moffitt roadmap. J Immunother Cancer. 2017 Jul.5:59. Pubmedid: 28725432. Pmcid: PMC5514522.
      • Locke FL, Neelapu SS, Bartlett NL, Siddiqi T, Chavez JC, Hosing CM, Ghobadi A, Budde LE, Bot A, Rossi JM, Jiang Y, Xue AX, Elias M, Aycock J, Wiezorek J, Go WY. Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma. Mol Ther. 2017 Jan.25(1):285-295. Pubmedid: 28129122. Pmcid: PMC5363293.
      • Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017 Dec.377(26):2531-2544. Pubmedid: 29226797. Pmcid: PMC5882485.
      • Locke FL. Highlights in Aggressive Non-Hodgkin Lymphoma From the 2017 American Society of Clinical Oncology Annual Meeting: Commentary. Clin Adv Hematol Oncol. 2017 Aug.15 Suppl 8(8):16-19. Pubmedid: 28837125.
      • Locke FL, Anasetti C. Transplanters drive CARs to the clinic by brewing ICE-T: the Moffitt roadmap. J Immunother Cancer. 2017 07.5(1):59. Pubmedid: 28716155. Pmcid: PMC5514522.
      • Locke FL, Menges M, Nishihori T, Nwoga C, Alsina M, Anasetti C. Boosting humoral and cellular immunity to pneumococcus by vaccination before and just after autologous transplant for myeloma. Bone Marrow Transplant. 2016 Feb.51(2):291-294. Pubmedid: 26457911. Pmcid: PMC5726387.
      • Khimani F, Jeong DK, Miladinovic B, Nishihori T, Ayala E, Locke F, Mishra A, Chavez J, Shah B, Gage K, Kharfan-Dabaja MA. Nonfluorodeoxyglucose-Avid Persistent Splenomegaly at Time of Transplantation Delays Neutrophil and Platelets Engraftment without Affecting Survival in Patients with Lymphomas Undergoing Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Tr. 2016 Dec.22(12):2201-2207. Pubmedid: 27660169.
      • Chavez JC, Piris-Villaespesa M, Dalia S, Powers J, Turba E, Nodzon L, Komrokji R, Sokol L, Locke FL, Lancet J, Sotomayor EM, Kharfan-Dabaja MA, Pinilla-Ibarz J. Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia. Leuk Res. 2016 Aug.47:78-83. Pubmedid: 27285853.
      • Tees MT, Betts B, Hillgruber R, Ayala E, Field T, Kharfan-Dabaja MA, Locke F, Mishra A, Nishihori T, Ochoa-Bayona JL, Perez L, Pidala J, Anasetti C, Fernandez H, Riches ML. New sources for argument: do HLA-C and HLA disparity in adult double umbilical cord blood transplants predict outcomes?. Bone Marrow Transplant. 2016 09.51(9):1256-1258. Pubmedid: 27088383.
      • Nelson R, Shapiro JF, Perkins JB, Kim J, Nishihori T, Pidala J, Ayala E, Locke FL, Field T, Mishra A, Riches M, Betts B, Perez L, Yue B, Ochoa-Bayona JL, Alsina M, Fernandez H, Anasetti C, Kharfan-Dabaja MA. Sirolimus, tacrolimus and antithymocyte globulin as GVHD prophylaxis in HLA-mismatched unrelated donor hematopoietic cell transplantation: a single institution experience. Bone Marrow Transplant. 2015 Nov.50(11):1487-1489. Pubmedid: 26301969. Pmcid: PMC4863975.
      • Locke FL, Menges M, Veerapathran A, Coppola D, Gabrilovich D, Anasetti C. Survivin-specific CD4+ T cells are decreased in patients with survivin-positive myeloma. J Immunother Cancer. 2015 May.3:20. Pubmedid: 25992291. Pmcid: PMC4437443.
      • Ayala E, Figueroa J, Perkins J, Kim J, Yue B, Riches M, Nishihori T, Locke F, Anasetti C, Kharfan-Dabaja MA. Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2015 Jun.15(6):335-340. Pubmedid: 25659459.
      • Pidala J, Kim J, Betts BC, Alsina M, Ayala E, Fernandez HF, Field T, Kharfan-Dabaja MA, Locke FL, Mishra A, Nishihori T, Ochoa-Bayona L, Perez L, Riches M, Anasetti C. Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial results. Biol Blood Marrow Tr. 2015 Jun.21(6):1074-1082. Pubmedid: 25805300. Pmcid: PMC5757506.
      • Pidala J, Kim J, Alsina M, Ayala E, Betts BC, Fernandez HF, Field T, Jim H, Kharfan-Dabaja MA, Locke FL, Mishra A, Nishihori T, Ochoa-Bayona L, Perez L, Riches M, Anasetti C. Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease. Haematologica. 2015 Jul.100(7):970-977. Pubmedid: 25840599. Pmcid: PMC4486232.
      • Zimmerman A, Locke FL, Emole J, Rosa M, Horna P, Hoover S, Dayicioglu D. Recurrent Systemic Anaplastic Lymphoma Kinase-Negative Anaplastic Large Cell Lymphoma Presenting as a Breast Implant-Associated Lesion. Cancer Control. 2015 Jul.22(3):369-373. Pubmedid: 26351895.
      • Locke FL, Rollison DE, Sondak VK. Merkel cell carcinoma and immunosuppression: what we still need to know. J Natl Cancer Inst. 2015 Feb.107(2). Pubmedid: 25575646.
      • Emole JN, Locke FL, Pinilla-Ibarz J. An update on current and prospective immunotherapies for chronic lymphocytic leukemia. Immunotherapy. 2015 Apr.7(4):455-466. Pubmedid: 25917633.
      • Chavez JC, Kharfan-Dabaja MA, Kim J, Yue B, Dalia S, Pinilla-Ibarz J, Anasetti C, Locke FL. Genomic aberrations deletion 11q and deletion 17p independently predict for worse progression-free and overall survival after allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia. Leuk Res. 2014 Oct.38(10):1165-1172. Pubmedid: 24889511. Pmcid: PMC4625795.
      • Kunter G, Perkins JB, Pidala J, Nishihori T, Kharfan-Dabaja MA, Field T, Fernandez H, Perez L, Locke F, Ayala E, Tomblyn M, Ochoa-Bayona JL, Betts B, Nieder M, Anasetti C. Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with ALL in first remission. Bone Marrow Transplant. 2014 Jan.49(1):11-16. Pubmedid: 23995098.
      • Locke FL, Nishihori T, Alsina M, Kharfan-Dabaja MA. Immunotherapy strategies for multiple myeloma: the present and the future. Immunotherapy. 2013 Sep.5(9):1005-1020. Pubmedid: 23998734. Pmcid: PMC4905571.
      • Locke F, Agarwal R, Kunnavakkam R, van Besien K, Larson RA, Odenike O, Godley LA, Liu H, Le Beau MM, Gurbuxani S, Thirman MJ, Sipkins D, White C, Artz A, Stock W. A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes. Bone Marrow Transplant. 2013 Nov.48(11):1437-1443. Pubmedid: 23771005. Pmcid: PMC4279870.
      • Pidala J, Kim J, Schell M, Lee SJ, Hillgruber R, Nye V, Ayala E, Alsina M, Betts B, Bookout R, Fernandez HF, Field T, Locke FL, Nishihori T, Ochoa JL, Perez L, Perkins J, Shapiro J, Tate C, Tomblyn M, Anasetti C. Race/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilization. Bone Marrow Transplant. 2013 Mar.48(3):346-350. Pubmedid: 22863723. Pmcid: PMC4500122.
      • Kharfan-Dabaja MA, Anasetti C, Fernandez HF, Perkins J, Ochoa-Bayona JL, Pidala J, Perez LE, Ayala E, Field T, Alsina M, Nishihori T, Locke F, Pinilla-Ibarz J, Tomblyn M. Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting. Biol Blood Marrow Tr. 2013 Jul.19(7):1087-1093. Pubmedid: 23632090. Pmcid: PMC4667782.
      • Locke FL, Zha YY, Zheng Y, Driessens G, Gajewski TF. Conditional deletion of PTEN in peripheral T cells augments TCR-mediated activation but does not abrogate CD28 dependency or prevent anergy induction. J Immunol. 2013 Aug.191(4):1677-1685. Pubmedid: 23851688. Pmcid: PMC3759681.
      • Zheng Y, Zha Y, Driessens G, Locke F, Gajewski TF. Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivo. J Exp Med. 2012 Nov.209(12):2157-2163. Pubmedid: 23129747. Pmcid: PMC3501351.
      • Pidala J, Kim J, Jim H, Kharfan-Dabaja MA, Nishihori T, Fernandez HF, Tomblyn M, Perez L, Perkins J, Xu M, Janssen WE, Veerapathran A, Betts BC, Locke FL, Ayala E, Field T, Ochoa L, Alsina M, Anasetti C. A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. Haematologica. 2012 Dec.97(12):1882-1889. Pubmedid: 22689677. Pmcid: PMC3590095.
      • Locke FL, Morgan GJ. What is the evidence for the use of bisphosphonate therapy in newly diagnosed multiple myeloma patients lacking bone disease?. Hematology Am Soc Hematol Educ Program. 2012.2012:350-353. Pubmedid: 23233603.
      • Pidala J, Tomblyn M, Nishihori T, Field T, Ayala E, Perkins J, Fernandez H, Locke F, Perez L, Ochoa JL, Alsina M, Anasetti C. Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids. Haematologica. 2011 Sep.96(9):1351-1356. Pubmedid: 21565902. Pmcid: PMC3166106.
      • Pidala J, Tomblyn M, Nishihori T, Ayala E, Field T, Fernandez H, Perez L, Locke F, Alsina M, Ochoa JL, Perkins J, Tate C, Shapiro J, Conwell M, Bookout R, Anasetti C. ATG prevents severe acute graft-versus-host disease in mismatched unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Tr. 2011 Aug.17(8):1237-1244. Pubmedid: 21215811. Pmcid: PMC5735843.
      • Locke F, Clark JI, Gajewski TF. A phase II study of oxaliplatin, docetaxel, and GM-CSF in patients with previously treated advanced melanoma. Cancer Chemother Pharmacol. 2010 Feb.65(3):509-514. Pubmedid: 19597729.
      • Locke FL, Artz A, Rich E, Zhang Y, van Besien K, Stock W. Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML. Bone Marrow Transplant. 2010 Dec.45(12):1692-1698. Pubmedid: 20208570.
      • Zha Y, Shah R, Locke F, Wong A, Gajewski TF. Use of Cre-adenovirus and CAR transgenic mice for efficient deletion of genes in post-thymic T cells. J Immunol Methods. 2008 Feb.331(1-2):94-102. Pubmedid: 18177887. Pmcid: PMC3278801.
      • Mattison RJ, Ostler KR, Locke FL, Godley LA. Implications of FLT3 mutations in the therapy of acute myeloid leukemia. Rev Recent Clin Trials. 2007 May.2(2):135-141. Pubmedid: 18473998.
    • Grants

      • Title: Accelerated Aging After Chimeric Antigen Receptor T-Cell Therapy (CART): Leveraging a Novel Population of Cancer Survivors to Elucidate Mechanisms of Dementia
        Sponsor: Nat Institutes of Health
        PI (Contact): Jim, H., PI (MPI): Locke, F.
      • Title: Kite Collaboration Master Agreement
        Sponsor: Kite Pharma
        PI: Locke, F.
      • Title: Neurocognitive and Patient-Reported Outcomes after Chimeric Antigen Receptor T-Cell Therapy: A Controlled Comparison
        Sponsor: Nat Institutes of Health
        PI (Contact): Jim, H., PI (MPI): Locke, F.
      • Title: Optimizing single cell sequencing to elucidate the relationship between response to brexucabtagene autoleucel (brexu-cel)and cellular determinants of exhaustion
        Sponsor: Kite Pharma
        PI: Shah, B., CO-PI: Yu, X., CO-PI: Locke, F.
      • Title: Clinical investigation to improve efficacy of CAR-T Cell Therapy for Large B Cell Lymphoma
        Sponsor: Leukemia & Lymphoma Society
        PI: Locke, F.

    Find a Researcher Search